2007 Corporate Responsibility Summary Report

Strong Actions
Partnering for Positive Change
We Pursue Innovative Solutions to Health Challenges Around the World.

Medical innovation is the core of our business. It’s a force for good—for patients, for those who seek to stay healthy, and for society at large. Yet our responsibilities and potential impact go far beyond the medicines we discover and develop. They include providing the value that our stakeholders seek.

We engage our stakeholders and partners to address society’s evolving needs on broad social, ethical and environmental fronts. There are many opportunities to partner on the safety of and access to our medicines, on new cures and treatments and on better health for people.

We also believe that good corporate responsibility can be a source of business innovation. New partnerships that address social needs through business practices can foster sustainable healthcare solutions. Pfizer seeks more of these linkages so we can help make the world better for our communities, our key stakeholders, and for all those who want a healthier tomorrow.
To Our Stakeholders,

I’m pleased to share with you Pfizer’s 2007 Corporate Responsibility Summary Report. Our focus is on sustainable health: investing in the health of communities and investing in the health of our business. This means at Pfizer, corporate responsibility must be the work of every part of our company—on every day.

And so you will see in these pages the tangible results throughout our company of commitment to one of our chief priorities: providing more value to our stakeholders. You will see new partnership and philanthropy models—and results. You will see how we are determined not just to comply with the law, but lead the way—for example by listing the status of our post-marketing studies—the first company to do so—and our new actions to improve health.

Finally, you will learn about the actions and results of thousands of Pfizer colleagues this report cannot mention but whose achievements we recognize. I applaud them all. They symbolize the new Pfizer: moving quickly to embrace innovation and improve the quality of life for people around the world.

Sincerely,

Jeff Kindler
Chairman and CEO
Operating with a New Stakeholder Model

Stakeholders are people or groups who affect, or are affected by, Pfizer’s business activities. We share with them an overarching goal—good health for all people at manageable costs, and a healthcare system that is sustainable.

Our relationships with stakeholders are at the heart of our corporate responsibility because they define what it means for Pfizer to create value. That is why, after being named CEO in July 2006, Jeff Kindler and the new senior management team met with a variety of stakeholders. They wanted to find out what was on stakeholders’ minds, what worked well—and what needed to be strengthened. Some of the company’s new priorities and actions are a result of these discussions. Following are just some of the stakeholders our senior management met with in the past year:

- American Heart Association
- American Lung Association
- American Medical Association
- Campaign for Tobacco Free Kids
- Easter Seals (disability services)
- Institutional and other shareholders
- International Alliance of Patients’ Organizations
- National Alliance for the Mentally Ill
- National and local government leaders
- Organization for Economic and Cooperation Development (OECD)
- Oxfam Great Britain and Oxfam America
- Pfizer colleagues around the world
- Pharmaceutical Industry Labor Management Association
- Sheet Metal Workers International Association
- Women Impacting Public Policy
- World Health Organization

Senior management heard a spectrum of comments from stakeholders, ranging from Pfizer being seen as an inflexible business partner, to questions about the stock price and from awe at Pfizer’s scientists for their skills and dedication, to surprise at the scope of our partnerships in improving access to medicines.

However, most stakeholders agreed that, given the complexity of public health problems facing the world today, no single entity—government, corporation, academic institution, nongovernmental organization, civic organization or others—could solve healthcare issues alone. It takes all of us working together, contributing our respective strengths.

Some stakeholders have different views on how to achieve healthcare goals. Our challenge is to build on areas of agreement and find common ground. To achieve this, we seek to constantly improve our communications and transparency, to listen and respond better to stakeholders, and to learn from them. We also share insights on how the pharmaceutical industry works as part of wider healthcare systems. We need strong and trusting partnerships to make progress on improving global health.

Given this reality, we will continue to engage stakeholders regularly and continue to share knowledge, skills and goals on how to prevent or manage diseases, get medicines to the people who need them, and promote good health among diverse populations. These partnerships take many forms as described in this Summary Report and in the full report on the web.

For full report, please see www.pfizer.com/crreport

Pfizer 2007 Corporate Responsibility Summary Report 3
Pfizer’s Old Stakeholder Model
Previously, we engaged with stakeholders one-on-one in areas of shared interest.

Pfizer’s New Stakeholder Model
Today, in a networked world, we focus on mutual goals—on pursuing innovative solutions to global health challenges with our stakeholders as partners. This also helps build economic prosperity.
Changing How We Integrate Stakeholder Needs

We are seeking to provide more social value today, as well as medical results, because that is what society is asking of us. By better serving our key stakeholders, we ultimately better serve our shareholders.

For a macro view of this change, please see the chart on page 4. We are also hiring a diverse workforce to reflect the diverse societies in which we operate. This is one way to give society a stronger “voice” within Pfizer—to employ in influential Pfizer positions colleagues from biotech firms, patient advocacy groups, health professional’s organizations, insurance providers, governments, think tanks and academia who influence our dialogue.

We also engage directly with stakeholders through issue advisory boards, employee surveys, conferences, small meetings and public-private partnerships. Some approaches have pre-defined feedback and follow-up methods. Other approaches are more informal and help shape future goals and activities. Here are two examples from early 2007:

Pharma Futures II—Prescription for Long-Term Value
www.pharmafutures.org

A senior Pfizer executive participated in Pharma Futures II, a dialogue initiated by pension funds with pharmaceutical companies to create a better understanding among all participants about the significant challenges in the health care sector, and the pharmaceutical industry’s role in finding solutions with other stakeholders. Participants discussed a range of subjects including the changing healthcare landscape around the world, biomedical R&D productivity, drug pricing, access to medicines, and clinical trials in emerging markets. The Pharma Futures II report is available at the website above.

Improved Patient and Medical Group Transparency

We continue to take significant steps to improve our transparency in how we partner with patient and medical organizations. For example:

In the United Kingdom
www.pfizer.co.uk/template4.asp?pageid=392

In the UK we are required, as a member of the Association of the British Pharmaceutical Industry, to publish a list of patient organizations we work with. Pfizer UK has also gone beyond the UK industry code and described the full nature of our relationships with these groups, as noted on our website above.

In the United States
www.pfizermededgrants.com

In the US, in 2008 we will develop a disclosure plan for educational grants and include stakeholders in our planning process, as noted on our website above. This will ensure stakeholders’ views are considered as the reporting process is developed.

Our Collective Action

Some social or environmental problems can only be solved by collective actions, when stakeholders from an entire industry or a cross-section of society band together for the greater good—when “all hands on deck” can provide solutions most effectively. We try to demonstrate our corporate responsibility by taking a leadership role in such collective actions, either within the biomedical community or in cross-sector initiatives. Examples include:

Global Environmental Management Initiative
www.gemi.org/waterplanner

GEMI is a coalition of companies committed to improving sustainable business practices. The Initiative’s recent effort is called “Collecting the Drops: A Water Sustainability Planner.” Pfizer played a leading role in developing this water sustainability tool by providing strategic direction on the approach and technical content, based on our own successes and challenges with managing water. The tool is on the website above.

Partnership for Quality Medical Donations
www.pqmd.org

PQMD is dedicated to advancing the quality of medical products delivered to underserved people and disaster victims around the world. Pfizer sponsored two key PQMD projects. We funded a study to develop a methodology for estimating the number of patients treated based on the volumes of medicines shipped to developing countries by PQMD members. We also funded and directed the creation of an educational film that teaches the basics of medical inventory management and raises awareness of the supply chain management profession globally. The film is available on the website above. PQMD’s current chairman is a Pfizer colleague.

United Nations Global Compact
www.globalcompact.org

This is a network of UN agencies, companies, nongovernmental organizations, labor groups and civil society that supports a shared set of principles on human rights, labor, environment and anticorruption. We joined in 2002 to show our commitment to good corporate responsibility. In 2007, Pfizer attended the Global Compact Leaders Summit in Geneva on “Facing Realities: Getting Down to Business.” This was an invitation-only event for chief executives, board members and presidents of countries or regional subsidiaries hosted by UN Secretary-General Ban Ki-moon. The summit focused on creating and supporting sustainable markets around the world. In addition, Pfizer signed “Caring for Climate: The Business Leadership Platform” to advance climate change solutions.
finding
CURES AND TREATMENTS

Our most important contribution is discovering, developing and delivering innovative medicines that society values to prevent and treat diseases.

To achieve these goals, we are committed to improving R&D productivity, increasing the transparency of our pipeline and clinical trial practices, improving drug safety monitoring, and working with stakeholders to advance the discovery and development of effective new medicines.
2006/2007 KEY ACTIONS

Continued to develop 242 research programs—the most Pfizer has ever had—spanning 11 therapeutic areas and enhanced disclosure of clinical trials.

Launched innovative new medicines to treat major diseases—for two hard-to-treat cancers, diabetes, tobacco dependence and bloodstream infections.

Established a collaboration with the World Health Organization to help find new compounds for diseases of the developing world.

Received FDA approval for Selzentry\textsuperscript{TM} (maraviroc), a breakthrough treatment for HIV/AIDS.


Partnered with the National Institutes of Health and biotech firms to unravel the genetic causes of common diseases.

Established a stem cell research policy to guide new external partnerships beginning in 2007. Please see www.pfizer.com/responsibility/stem_cell_research.jsp.

Launched the mainstream pharmaceutical industry’s first “incubator,” which supports early-stage research start-ups.

Launching Medicines for Unmet Medical Need

In 2006, we introduced several innovative medicines that are expected to have far-reaching impact. They include:

\begin{itemize}
  \item **Sutent\textsuperscript{®}**
  Sutent\textsuperscript{®} is the first medicine ever to be approved simultaneously by the FDA to treat two types of deadly cancer—advanced renal cell carcinoma, a type of kidney cancer, and gastrointestinal stromal tumor, known as GIST. Also approved to treat these diseases by the European Union, Sutent\textsuperscript{®} not only kills cancer cells but starves the tumors of blood and nutrients. We are now investigating its efficacy in breast, lung and colorectal cancers.
  \item **Chantix\textsuperscript{®}**
  Chantix\textsuperscript{®} is our smoking-cessation medicine. It works by reducing the severity of the smoker’s urge to smoke, while diminishing the sense of satisfaction if a patient smokes during treatment. It’s offered with a personalized patient support program called GetQuit, to help smokers quit. According to a range of healthcare experts, helping smokers quit is one of the most important things a physician can do to improve their patients’ overall health and reduce the risk of developing serious chronic conditions.
  \item **Exubera\textsuperscript{®}**
  Exubera\textsuperscript{®} is the first inhalable form of insulin. It meets a critical medical need to manage Type 1 and Type 2 diabetes in adults, by offering a highly effective alternative to pills and insulin injections. The global incidence of diabetes is currently at epidemic levels. Millions of patients are not achieving or maintaining acceptable blood sugar levels, despite the availability of current therapies.
  \item **Eraxis\textsuperscript{®}**
  Eraxis\textsuperscript{®} treats candidemia, the most deadly of the common hospital-acquired bloodstream infections, which can spread quickly, especially for patients with weakened immune systems. Eraxis\textsuperscript{®} is an important new treatment for the approximately 60,000 patients in the US who contract this dangerous infection each year.
  \item **Lyrica\textsuperscript{®}**
  In June 2007, the FDA approved Lyrica\textsuperscript{®} for the management of fibromyalgia, a common chronic and widespread pain condition. The approval represents a breakthrough for the more than six million Americans who previously had no FDA-approved treatment options. This is Lyrica’s\textsuperscript{®} fourth FDA-approved indication which was initially approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia and for adjunctive use in the treatment of epilepsy.
\end{itemize}
Bringing an R&D Pipeline Strategy to Life

Improving R&D productivity is a top priority for us. We determine R&D priorities according to medical need, followed by breakthrough potential, obstacles and commercial opportunities. Four of our 11 therapeutic areas of concentration include:

1. **Cardiovascular, Metabolic and Endocrine Disease**
   We have seven main areas of focus—atherosclerosis, hypertension, obesity, diabetes, bone and muscle health, thrombosis and growth hormone deficiency. Drug candidates in late stage development include a potential new treatment for obesity now in Phase III studies.

2. **Oncology**
   The number of oncology R&D projects at Pfizer has increased four-fold over the past five years. Pfizer currently has 212 clinical trials under way in oncology, the most in the industry. Late stage development projects include Phase III trials against melanoma, pancreatic, thyroid, colorectal, lung and breast cancer.

3. **Neuroscience**
   This portfolio includes new drug targets in areas of critical medical need—Alzheimer’s disease, pain, cognition and attention-deficit / hyperactivity disorder, depression and anxiety, and sleep disorders. Pfizer’s Lyrica®, the company’s new medicine for neuropathic pain, was recently approved by the FDA for the treatment of fibromyalgia, characterized by chronic, widespread pain.

4. **Infectious Diseases**
   We are targeting key bacterial agents and key viral diseases. Pfizer is breaking new ground in our approaches to the treatment of HIV/AIDS, especially with the recent FDA approval of Selzentry™. We are also exploring a number of other R&D approaches to find new treatments for HIV/AIDS.

Expanding Research for Diseases of the Developing World

We believe we have a responsibility to conduct and support research for diseases that affect the developing world. We are expanding our efforts to help meet this world health challenge. As a single company, however, we are limited in our ability to solve such universal health problems and recognize that multi-sector solutions are needed. Today, public-private partnerships are essential to making progress on this front.

Collaborating with the World Health Organization

Our collaboration with the WHO’s Special Program for Research and Training in Tropical Diseases (WHO/TDR), announced in October 2006, is an unprecedented partnership for a public company. We are opening our library of medicinal compounds—the world’s largest—to help search for new antiparasitic medicines against such deadly diseases of the developing world as malaria, leishmaniasis, African trypanosomiasis, onchocerciasis, schistosomiasis and Chagas’ disease. We will also bring scientists from developing countries into our laboratories for training in drug discovery techniques.

Improving Treatments for Malaria

Through our Zithromax®/chloroquine clinical trial program, Pfizer scientists are developing a potential malaria treatment based on our widely used antibiotic, Zithromax®. Dosed in combination with chloroquine, Zithromax® demonstrated positive results in the treatment of adults with malaria in Africa. Currently, clinical studies are ongoing at centers in South America, India and Africa.

Launching a New Breakthrough Medicine for HIV/AIDS

In August, 2007, the FDA approved Selzentry™ (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry™ blocks the virus’s entry into white blood cells, providing a significant alternative for treatment-experienced patients infected with a specific type of HIV. A solid breakthrough, it is expected to help where currently available therapies have failed. Celsentri® also received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe. We are actively engaging key external stakeholders to determine how to best facilitate responsible access to Celsentri® in developing world countries based on its utility and approved indication.
Increasing Pipeline Transparency
We now are posting information about our pipeline on www.pfizer.com/pipeline—where doctors, patients and the public can track our progress. With a pipeline that is 250 percent larger than it was just six years ago, the website provides details on all major products in all key disease areas.

Increasing Clinical Trial Transparency
With the expansion of our clinical trials disclosure policy in January 2007, we now register every Pfizer-sponsored clinical study in patients on the NIH-sponsored website www.clinicaltrials.gov. This includes Phase 1 trials and non-interventional studies with prospective data. For every trial Pfizer registers, we also disclose the results in the PhRMA results database (www.clinicalstudyresults.org). As of August 8, 2007, Pfizer registered 842 studies on the NIH site and posted 554 studies on the PhRMA results site. This policy builds on our previous commitment from 2005. Please also see www.pfizer.com/research/clinical_trials.jsp.

Pursuing a Humane Approach to Animals
We understand stakeholders’ concerns about the use of animals in research testing. Based on our Animal Welfare policy, we proactively look for alternatives that reduce, replace or refine our work with animals. To adopt new nonanimal test methods, we engage in and lead cross-industry efforts aimed at developing and refining new and promising testing and information systems that may help predict medical outcomes. Currently and for the foreseeable future, it is only through the combination of animal-based research and alternatives that we can understand the fundamental biology of the diseases we are trying to treat, discover new medicines for and assess their safety.

Facing Developing World Challenges
Pharmaceutical companies face unique challenges when conducting clinical trials in countries with weak medical and regulatory infrastructures. Pfizer is facing such a challenge. The case concerns a clinical trial of Pfizer’s antibiotic, Trovan, and children suffering from meningitis during a meningitis epidemic in Kano, Nigeria in 1996. In June 2007, Kano and federal authorities filed civil and criminal lawsuits in Nigeria against Pfizer.

One allegation is that Pfizer failed to obtain proper informed consent from the children’s families. As Pfizer stated in its response to this action, Pfizer acted in the best interest of the children and used the best medical knowledge available to treat patients. Before any child was admitted to the study, the entire process for conducting the trial was explained to each parent or guardian in their native language, and consent was obtained orally. The parents or guardians were allowed to remain with and see their children during the treatment. The study was conducted with the necessary approvals from the relevant government agencies in an ethical way consistent with Pfizer’s commitment to patient safety. Trovan proved safe and effective. The study’s survival rate for Trovan and the comparative drug exceeded the survival rate of any other treatment at the Infectious Disease Hospital in Kano.

Increasing Scientific Collaborations and Partnerships
We are increasingly engaging in new and different approaches to maximize the potential of our R&D activities—in the form of scientific alliances and partnerships with academia, public research institutions, foundations, nongovernmental organizations, biotechnology companies and governments. Examples include:

Collaborating with The Scripps Research Institute
In December 2006, we announced a five-year research collaboration with The Scripps Research Institute to study and evaluate possible therapeutic approaches for such uncured diseases as cancer, diabetes and mental illness.

The FDA’s “Critical Path” Initiative
Pfizer has been actively involved in this cooperative initiative, which is aimed at improving the scientific and regulatory processes that can turn new science into better medical treatments. The initiative has stimulated the formation of public-private partnerships such as the Biomarkers’ Consortium.

The Biomarkers Consortium
With Pfizer’s active participation, the Foundation for the National Institutes of Health (FNIH), the FDA, the NIH, and the Pharmaceutical Research and Manufacturers of America (PhRMA) launched this public-private research partnership in October 2006. The Consortium sponsors projects to discover, develop and qualify new biological markers—molecular or biological indicators that help identify risk for disease, make a diagnosis or assess drug safety.

Incubating Science Innovation
Pfizer recently launched the mainstream pharmaceutical industry’s first “incubator” at our LaJolla, California laboratory. Pfizer provides funding and laboratory space in support of early-stage research conducted by academics and small biotech start-ups. This way, we are closer to external innovation and cutting-edge ideas and the scientists can focus on science rather than worrying about funding and logistics.

AWARDS AND RECOGNITION

- Two Pfizer scientists, along with a non-Pfizer scientist, were presented in March 2007 with the PhRMA Discoverers Award for Zyvox®.
- A Pfizer scientist was appointed to the US National Human Genome Advisory Council in 2006.
investing

IN HEALTH

Improving access to medicine and strengthening healthcare systems for underserved people around the world are among the standards by which our success as a pharmaceutical company is measured.

To that end, we are working on new solutions with our partners. We are investing in effective and sustainable healthcare delivery resources, and working with governments, nongovernmental organizations, multilateral organizations, academic institutions and others to help people get the medicines and services they need.
Implementing a Holistic Approach to Healthcare Delivery

Making medicines accessible around the world requires a commitment on many fronts: engaging and educating providers and patients about diagnosis and treatment; building healthcare capacity; delivering the medicines where they need to be, when they need to be there; and partnering effectively with organizations treating patients on the ground. We are committed to working with our partners to establish meaningful and enduring programs that advance healthcare delivery to underserved people around the world.

Treat, Teach, Build, Serve

To invest in effective and sustainable delivery of healthcare resources and expertise for underserved people around the world, Pfizer coordinates its efforts under four major areas of support—treat, teach, build and serve. The programs on this and the next two pages are examples of programs that contribute in all four areas. We define them as:

- **TREAT** Improving access to medicines and health care services.
- **TEACH** Increasing patient education and health worker training on health issues and prevention.
- **BUILD** Working to strengthen healthcare organizations and improve their ability to serve their patients and communities.
- **SERVE** Advocating for improved healthcare for the underserved and sharing best practices to improve healthcare delivery.

2006/2007 Key Actions

- Launched “Mobilize Against Malaria” with NGO partners and three African governments to help close gaps in malaria treatment.
- Launched ConnectHIV, to support community-based AIDS service organizations working to stop the spread of HIV/AIDS in the US.
- Launched Global Health Partnerships to support public health programs in oncology and tobacco dependence.

Mobilize Against Malaria

Malaria is Africa’s leading cause of child mortality. We have made a commitment to help close critical treatment gaps in malaria for patients in Senegal, Ghana and Kenya. This effort through the Clinton Global Initiative (www.clintonglobalinitiative.org) includes engaging in partnerships with governments, NGOs and leading local and international organizations to help develop and strengthen access to treatment, provider training and patient education programs for malaria.

In partnership with Pfizer’s global evaluation team from the London School of Hygiene and Tropical Medicine, each pilot intervention has been designed to reduce the rate of malaria morbidity and mortality by improving malaria symptom recognition, treatment, and referral through:

1. Targeted training activities to improve the quality of treatment
2. Complementary community mobilization campaigns to better support patients and strengthen the demand for quality care. Specifically, each program works to ensure pregnant women and children under five are seeking treatment appropriately within 24 hours.

Pfizer is partnering with leading NGOs and local evaluation teams to develop robust and measurable programs that will advance malaria control efforts and that have the potential to be replicated and scaled up by collaborating institutions.

The Pfizer Mobilize Against Malaria initiative represents the four key components of our investment efforts in the following ways:

- **TREAT** Increase the number of patients receiving prompt and appropriate malaria treatment.
- **TEACH** Train providers and healthcare workers to improve patient diagnosis, treatment and referral.
- **BUILD** Enhance the effectiveness of the informal and public sectors in the delivery of appropriate treatment for malaria.
- **SERVE** Partner with the London School of Hygiene and Tropical Medicine to evaluate the effectiveness of malaria interventions and share knowledge and learnings with the Ministries of Health and other stakeholders with the resources to expand best practices throughout the targeted countries.
International Trachoma Initiative

This public-private partnership, which Pfizer helped found and continues to support, is dedicated to eliminating trachoma, the world’s leading cause of preventable blindness, through health worker training, patient education and donations of the Pfizer antibiotic, Zithromax® (azithromycin).

The ITI has given 54 million treatments of Zithromax® to trachoma patients in 13 countries as part of the WHO SAFE strategy (Surgery, Antibiotics, Face-Washing and Environmental Improvement). Since 1998 the program has supported the training of thousands of healthcare workers around the world who, in turn, have completed more than 277,000 surgeries to treat advanced cases of trachoma.

For example, in Niger, the collaboration between the Ministry of Health and ITI has supported more than 27,000 trichiasis surgeries and the treatment of 8 million people with Zithromax® since the program’s inception. The program’s has reduced the prevalence of trachoma from over 60 percent to 7 percent in some regions of Niger.

In 2006, after six years of work, Morocco became the first country to complete the campaign for trachoma control and is working toward WHO certification that blinding trachoma has been eliminated as a public health problem.

• **TREAT** Help improve treatment education and increase adherence to treatment protocols for those who are infected.

• **TEACH** Support ASOs that take a comprehensive approach to prevention practices and access to care, and develop a collaborative network of ASOs that share replicable program models and best practices.

• **BUILD** Support and enhance the capabilities of ASOs through technical assistance and professional training so they can reach as many underserved people as possible.

• **SERVE** Partner with the Academy for Educational Development and Johns Hopkins Bloomberg School of Public Health—leaders in the HIV community—to measure the impact of ConnectHIV and share lessons learned and best practices with other organizations addressing the HIV/AIDS epidemic.

ConnectHIV

The Pfizer Foundation is providing $7.5 million in grants, technical assistance and networking resources over three years (2007-2010) to 20 mid-sized AIDS service organizations (ASOs) in the 10 states of the US with the highest number of new AIDS cases. ConnectHIV programs will serve communities that are disproportionately affected by HIV/AIDS, including African-Americans, Latinos, women, low-income communities, individuals engaging in high-risk behaviors, people who are homeless or in unstable housing, people with persistent mental illness, and the incarcerated.

The program aims to prevent new infections to high-risk populations and delay disease progression for those already infected by supporting ASOs that take a comprehensive approach to prevention, access to care and treatment. A review committee consisting of internal and external HIV/AIDS experts reviewed over 115 applicants to choose the 20 ASOs that will receive support. Criteria included a commitment to the HIV/AIDS prevention and care continuum; the ability to reach underserved, multicultural communities; evaluation expertise; and the potential for program replication.

• **TREAT** Help improve treatment education and increase adherence to treatment protocols for those who are infected.

• **TEACH** Support ASOs that take a comprehensive approach to prevention practices and access to care, and develop a collaborative network of ASOs that share replicable program models and best practices.

• **BUILD** Support and enhance the capabilities of ASOs through technical assistance and professional training so they can reach as many underserved people as possible.

• **SERVE** Partner with the Academy for Educational Development and Johns Hopkins Bloomberg School of Public Health—leaders in the HIV community—to measure the impact of ConnectHIV and share lessons learned and best practices with other organizations addressing the HIV/AIDS epidemic.
Global Health Fellows

In 2003 Pfizer launched the Pfizer Global Health Fellows program, which calls on our talented, committed and trained employees to work in Africa, Asia, Eastern Europe and Latin America for three-to-six-month periods. So far, more than 128 Fellows have been selected to work with 26 nongovernmental organizations in 31 countries to deliver healthcare and health system support to those in need around the world.

- **TREAT** Help NGOs improve and expand patient treatment and increase adherence to treatment protocols where the need is greatest.
- **TEACH** Train providers and healthcare workers to improve patient diagnosis, treatment and referral. Educate patients on healthy behaviors.
- **BUILD** Support and strengthen the public sector healthcare infrastructure and sanitation facilities through hands-on management of construction projects and related systems.
- **SERVE** Seek partners and funding sources in countries where Fellows are assigned to improve healthcare for the underserved.

Alliance for a Healthy Border

In and around the US-Mexico border, the Hispanic population is struggling with disproportionately high rates of diabetes and cardiovascular disease. We have joined US community health centers, Mexican community organizations and the University of Texas-Pan American to prevent these diseases from striking in the first place and to stop their progression among people already living with these diseases. We are providing grants to community health centers in four US border states, as well as community organizations in Mexico, to promote best practices in prevention and disease management.

- **TREAT** Provide grants to community health centers that provide treatment to patients who otherwise might not receive it.
- **TEACH** Provide prevention education and disease management techniques to Hispanic populations that suffer disproportionately from diabetes and cardiovascular disease.
- **BUILD** Strengthen the capabilities of community health centers through technical assistance and training.
- **SERVE** Partner with the University of Texas-Pan American to measure the impact of program interventions; share lessons learned and best practices with other organizations committed to improving Hispanic health.
Programs Around the World

In addition, we support a range of sustainable healthcare delivery resources to help underserved people around the world get the care and treatments they need.

**TREAT** Improving access to medicines and healthcare services

**MULTI-COUNTRY** **Diflucan Partnership Program**
Pfizer donates Diflucan® (fluconazole), a medicine that treats two fungal opportunistic infections associated with HIV/AIDS, to governmental and nongovernmental organizations in developing countries. The program has donated approximately $570 million in medicine in 59 countries, and since 2000 has supported the training of 20,000 health professionals.

**UNITED STATES** **Pfizer Helpful Answers**
This is a group of programs to help Americans without prescription coverage save money on Pfizer medicines, regardless of age or income. Patients with limited incomes may also qualify to get their Pfizer medicines for free. Pfizer is also a member of the Partnership for Prescription Assistance (PPA), a coalition of stakeholders that in two years has helped more than 3.6 million qualifying patients get the medicines they need.

**BUILD** Working to strengthen healthcare organizations and expand their ability to serve their patients and communities better

**UGANDA** **Infectious Diseases Institute**
Pfizer partners with several leading organizations to support training, treatment and research activities of the Infectious Diseases Institute (IDI) in Kampala, Uganda. Since 2004, the IDI has trained more than 1,400 healthcare providers from 26 African countries, and provides prevention, care and treatment to approximately 10,000 patients annually.

**MALAYSIA** **Health Screenings**
Care-A-Van is a Pfizer-sponsored initiative endorsed by Malaysia’s Ministry of Health. It provides free health screenings and health education, especially for less privileged populations. Since its launch in 1999, the van has visited more than 186 locations and screened more than 80,000 patients nationwide.

**TEACH** Increasing patient education and health worker training on health issues and prevention

**MULTI-COUNTRY** **Reducing Cancer and Tobacco Use**
We are launching a new global initiative to improve cancer-related health outcomes and/or encourage tobacco independence. In one program, partners in Mexico, Brazil, Colombia, Argentina, Costa Rica and Venezuela will receive funds and technical assistance from the American Cancer Society to support detection and screening services for underserved patients and build cancer patient advocacy capacity.

**UNITED STATES** **Southern HIV/AIDS**
The Pfizer Foundation and Pfizer committed $6 million over three years, beginning in 2004, to support a network of more than 55 HIV/AIDS prevention programs across nine Southern US states. As a result, more than 1,000 individuals were trained as peer educators, 3,000 individuals received testing and/or counseling, more than 11,000 referrals were made, and more than 50,000 community members received prevention materials.

**SERVE** Advocating for improved healthcare for the underserved and sharing best practices to improve healthcare delivery to this population

**CHINA** **Educating on Chronic Diseases**
Working with the local Beijing and Shanghai governments on their health priorities, Pfizer initiated programs to help physicians and patients learn to prevent, diagnose earlier and treat chronic diseases such as HIV/AIDS, cardiovascular diseases, stress management and smoking cessation. The learnings from these partnerships have a ripple effect throughout the local communities.

**RUSSIA** **Workplace Healthiness**

**AWARDS AND RECOGNITION**

- Pfizer was voted top corporate giver by the Chronicle of Philanthropy in 2006.
- Pfizer Hong Kong received the Gold Award from the Hong Kong Social Welfare Department in recognition of their commitment to volunteerism.
- Pfizer Global Health Fellows received the first annual Corporate Citizenship award from Global HR News in May 2007.
strengthening

PATIENT SAFETY

Patient safety is our top commitment.

To make sure our medicines are safe and effective, we have a rigorous evaluation process that starts at the very earliest stages of drug discovery and continues long after our medicines are on the market. We continue to take new actions to improve our transparency and communications about safety.
Identifying, Analyzing and Reporting Safety Data

We employ about 2,000 professionals—including physicians, nurses, pharmacists, medical research scientists and statisticians—who are dedicated to patient safety. Their sole responsibility is to identify, analyze and report potential safety issues at every point in the life of a medicine. Pfizer scientists use information reported by physicians, patients and caregivers, as well as peer-reviewed journals and medical literature, to detect health risks as early in a medicine’s life-cycle as scientifically possible. In partnership with outside experts and health authorities, we thoroughly evaluate all reported potential safety concerns and communicate risks to physicians and patients in the most timely way possible.

2006/2007 KEY ACTIONS

Established a new medical governance process that strengthens internal coordination and accountability throughout product lifecycles.

Launched a public website to disclose safety studies of our medicines after they are on the market.

Strengthened anti-counterfeiting efforts by introducing new packaging and shipping technology.

Strengthening Medical Governance

In response to new challenges and stakeholder concerns about the safety of medicines, we have established a new medical governance process that strengthens coordination and accountability among the medical and safety organizations responsible for the benefit/risk profiles of our investigational and approved medicines. This new process is comprised of a thre-tiered Medical Review Committee structure:

1. The Product Medical Review Committees are composed of our product teams, as well as medical, safety, regulatory and legal representatives. These committees oversee the development and maintenance of the benefit/risk profile of specific compounds.

2. The Therapeutic Area Medical Review Committees are composed of senior therapeutic area medical, safety, regulatory and legal management. These committees provide primary oversight and support of the Product Medical Review Committees, as needed.

3. The Executive Medical Review Committee is chaired by the Chief Medical Officer and senior management. This committee provides oversight, direction and resolution of conflicts arising from the legitimate diversity of medical opinion that can often exist. These procedures were designed in response to Pfizer’s increased scale, the critical importance of reaching clear medical decisions on a timely basis, and the need for transparency in Pfizer’s medical decision-making process, both internally and externally.
Communicating About Safety to Key Stakeholders

In addition to assuring best practices internally, we are taking steps to broaden safety awareness and continuously improve safety communications. These include:

- Making information on our medicines’ labeling easier to understand
- Developing and continually updating brochures for doctors and patients that explain the appropriate use of our medicines
- Producing safety training materials for physicians who conduct clinical trials and
- Providing clearer safety information on our product websites to help patients understand the safety issues involved with the medicines they are taking.

Working with Regulators

We want to make sure the medicines we develop and produce are approved and monitored by strong, effective and rigorous regulatory agencies. That’s why we support a drug regulatory framework that is well funded and effectively managed, both pre- and post-approval. We are committed to working with regulatory agencies, governments and other stakeholders to address concerns about drug safety. In the US, we support proposals that will strengthen the FDA’s ability to conduct regular surveillance, identify new safety signals and hypotheses, and communicate risks to patients and health professionals. And we strongly support proposals that require mandatory risk management plans, which we already include in our drug application submissions.

Conducting Post-Marketing Studies

Our safety research and assessment continues throughout the life of a drug because additional risks or benefits can become apparent after a medicine reaches a broader and larger patient population. In fact, working with regulators and using the best scientific methods and new information-gathering technologies, we proactively develop long-term studies of large patient populations in real-world clinical practice environments to help further ensure patient safety once a medicine is available. Our experiences with Exubera, our inhaled insulin product, and Celebrex, our medicine for arthritis pain, are key examples, where we have committed hundreds of millions of dollars to fund independent studies.

Pfizer’s Post-Marketing Transparency

We understand concerns from some stakeholders about the lack of information on the safety of medicines once they reach the marketplace. To address this concern, we took an important step in leading public accountability—the launch in May 2007 of our online post-marketing transparency initiative.

Through this initiative, we launched a website to provide up-to-date, user-friendly information on the status of our US post-marketing commitments. Post-marketing commitments (PMCs) are studies conducted after a medicine receives regulatory approval, often as a requirement for approval or continued marketing of some medicines. The studies are designed to provide additional information about the medicine’s safety, efficacy or optimal use. This initiative is the first of its kind for a pharmaceutical company.

Our website provides study descriptions and the status of US FDA post-marketing commitments, current due dates, total listed Pfizer PMCs, and general information about the PMC process. It is now available at www.pfizer.com/pmc.

“This kind of transparency helps encourage patients to ask their physicians about treatment options. When these conversations happen, they often help patients better understand the risks and benefits of different treatment options.”

— DR. JOSEPH FECZKO, CHIEF MEDICAL OFFICER
Deterring Medicine Counterfeiting to Protect Patient Safety

Pharmaceutical counterfeiting is on the rise, potentially putting at risk millions of patients who assume the prescription medicines they take are safe and effective. To address this issue, Pfizer’s anti-counterfeiting program, with a staff of 17 full-time professionals, partners with law enforcement agencies around the world, has invested in state-of-the-art forensic facilities and provided 40 training programs for enforcement and regulatory authorities in 17 countries. Our partnerships with those agencies have helped to dismantle counterfeiting operations in more than 20 countries.

Using New Tools and Techniques
In addition to investigating and prosecuting counterfeiters, we also review the integrity of the supply chain and have introduced new high-security measures that include color-shifting ink logos and tamper-evident packaging as authentication tools for pharmacists and doctors. In our latest initiative, we have begun a program to ship a medicine containing radio frequency identification (RFID) tags to customers in the United States, so pharmacies and wholesalers can verify the unique electronic product code on the packaging. We are the first pharmaceutical company to put in place a program of this kind.

Improving Safety in the Drug Distribution Chain
Meanwhile, Pfizer has developed model legislation that strives to help prevent counterfeit drugs from entering the pharmaceutical distribution system. This legislation imposes criminal background checks and criminal penalties for counterfeiting, establishes licensing requirements for secondary wholesalers, and requires “change-of-ownership” documentation if medicines leave the traditional distribution chain. Working with law enforcement agencies and many other stakeholders since 2004, anti-counterfeiting legislation has passed in 25 states, with the remaining 25 states either considering or introducing similar laws. We are also working with stakeholders to develop national legislation with provisions that mirror those of the state laws.

How do you know if you’ve purchased a counterfeit medicine?
In some cases, patients later identified that counterfeits have a different taste, odor, consistency or appearance. Patients also may have a different reaction to the counterfeit drug.

AWARDS AND RECOGNITION

- Pfizer received an International Association of Business Communicator’s Gold Quill Excellence Award for communications materials developed for the Coalition Against Fake Medicines.
- Pfizer was chosen by CIO (Chief Information Officer) magazine to receive its CIO 100 award in 2007, for using information technology effectively to create value.
- Food & Drug Packaging magazine named Pfizer’s Amboise, France, manufacturing facility a 2006 Plant of the Year for its RFID pilot program used for Viagra packaging.
Improving Our Business Practices

*What* we do at Pfizer contributes to society’s overall health.

*How* we do it is equally important to the well-being of people and the planet.

Working with our stakeholders, we welcome mutual accountability as society’s expectations continue to evolve.
ENVIRONMENT, HEALTH AND SAFETY

2006/2007 KEY ACTIONS


Implemented more than 400 energy and water conservation measures in 2006, reducing CO₂ emissions by more than 69,000 metric tons and water consumption by 21 million cubic meters.

Met Volatile Organic Compounds (VOC) goal two years in advance of 2008 target.

Increased ISO 14001 and OHSAS 18001 certifications, OSHA VPP status, and participation in the US EPA National Environmental Performance Track program.

Partnered with the Alliance to Conserve the Maya Forest to promote sustainable growth in the second largest rainforest in the Americas.

Continued in our second year using 30 percent post-consumer content recycled paper as the preferred paper for all US-based operations.

Climate Change: Reducing Greenhouse Gases and Using Energy Wisely

Pfizer’s Climate Change and Energy Program seeks to minimize the cost and operational restrictions arising from a carbon-constrained environment, reduce Pfizer’s contribution to greenhouse gas (GHG) emissions, and assess the risk presented to Pfizer’s operations from the potential physical changes resulting from a warming global climate. Pfizer is a charter member company of the US EPA Climate Leaders Program. It is a voluntary industry-government partnership that works with companies to develop long-term, comprehensive climate change strategies.

Pfizer is also working to reduce the impact of our nearly 38,000 vehicles worldwide. We are conducting a pilot program in 2007 to field test hybrid vehicles to help increase fuel economy and reduce potential GHG emissions.

Reducing Air and Waste Emissions

Our commitment to reduce the environmental impact of our operations includes reducing our emissions to the air, minimizing the waste we produce and maximizing our use of recycled materials. We are also committed to effectively managing any waste we generate to eliminate its potential impact on human health and the environment.

Realizing the Promise of Green Chemistry

As a leader in Green Chemistry (GC), using environmentally-friendly Green Chemistry practices has improved our production of several products while reducing waste and costs. Green Chemistry is integrated internally and promoted through outreach activities such as workshops and conferences for universities and curricula for middle schools.

COMPANYWIDE GOALS

Climate Change

To reduce carbon dioxide emissions by 35 percent per million dollars of sales by 2007 from our baseline 2000 year.

Clean Energy

To meet 35 percent of our global electricity needs by 2010 through “clean” energy sources.

Ozone Depleting Compounds (ODCs)

To phase out the use of Class 1 ODCs in large heating, ventilation, air conditioning and industrial process equipment.

Ozone Depletion Potential (ODP)

To reduce our ODP from ODC releases by the end of 2007 by 80 percent from our 2002 baseline.

Volatile Organic Compounds (VOCs)

To reduce our releases of VOCs by 40 percent, on an absolute basis from the baseline year of 2002 by the end of 2008.

AWARDS AND RECOGNITION

→ Honored with the National Award from the Irish National Safety Organization to our Ireland-based manufacturing sites.

→ The Kalamazoo, Michigan site achieved program recertification from the Wildlife Habitat Council.

→ In October 2006, the UK Institute of Chemical Engineers recognized Pfizer for Green Chemistry practices for Lyrica® and Vfend®. Lyrica® won the top European Green Chemistry award and Vfend® was a finalist for the Faraday Award.
2006/2007 KEY ACTIONS

Strengthened the link between executive compensation and Pfizer's financial performance.

Initiated face-to-face meetings with institutional investors and the Board.

Adopted a new international procedure to improve our implementation of the US Foreign Corrupt Practices Act.

Code of Business Conduct

Our ability to be viewed as a trusted member of society begins with Pfizer's Policies on Business Conduct. Pfizer Directors are required to comply with a Code of Business Conduct and Ethics designed specifically to cover all areas of professional conduct relating to service on our Board.

Colleagues worldwide receive the Summary of Pfizer Policies on Business Conduct (or “Blue Book”) and must sign a statement acknowledging that they have read it and will abide by it. The Blue Book has been translated into 45 languages. These policies are available at www.pfizer.com/corpgov.

Instituting Greater Accountability in Executive Compensation

Jeff Kindler became Pfizer's CEO in July 2006. The Board of Directors directed that his compensation plan provide a tight link between his future pay and near- and long-term value creation for Pfizer shareholders. He does not have an employment contract, and his retirement benefits are based on the same formula as other salaried Pfizer employees.

Meeting Face-to-Face

Pfizer is the first company to initiate a regular meeting between its Board and institutional investors on governance. The Board will invite representatives who evaluate governance practices and who vote the proxies of the company’s largest institutional investors. These representatives own in aggregate approximately 35 percent of Pfizer’s shares. The initial meeting is planned for the fall of 2007.

Preventing Bribery and Corruption

We implemented, in April 2007, the International Anti-Bribery and Anti-Corruption Corporate Procedure, to continually improve on our ability to adhere to all provisions of the Foreign Corrupt Practices Act. We also developed an implementation platform to help local teams train colleagues and adopt local procedures.

SALES AND MARKETING

2006/2007 KEY ACTIONS

Implemented guidelines for more beneficial prescription medicine advertising.

Implemented ACE (Aligning Customer Excellence) program in Europe to better meet stakeholders’ needs.

Rolled out a code of conduct on interactions with healthcare professionals in 45 languages in more than 100 countries.

United States: Delivering Beneficial Prescription Medicine Advertising

Data supports appropriate direct-to-consumer advertising as an important method of educating patients and supporting the patient/doctor relationship.

However, some stakeholders are concerned about the use of prescription medicine advertising.

In 2006 we implemented new advertising guidelines for our prescription drug advertising. Some specific commitments include reviewing TV ads in advance with the FDA and using consumer-friendly summaries in print ads.

Europe: Aligning Customer Excellence (ACE)

ACE aligns Pfizer Europe to stakeholder interests in the European healthcare marketplace. Through ACE we have allocated resources in Europe so we can interact more flexibly with a range of stakeholders who provide us direct feedback that helps us address their concerns and interests. Patient groups, the public at large, payers, government and health officials, and physicians’ and nurses’ groups are all increasingly organized to advise us in this capacity.

Global: Implementing a Global Marketing Code of Conduct

In 2006, we fully rolled out the Pfizer Global Policy on Interactions with Healthcare Professionals in more than 100 countries. The policy, written in 45 languages, provides specific guidelines for Pfizer colleagues who have direct contact with healthcare professionals. It covers such topics as Pfizer-hosted educational meetings, medical communications, marketing activities, confidentiality of patient data and the use of gift items.

AWARDS AND RECOGNITION

Rated the top company in our peer group by Governance Metrics International in April 2007.

For an unprecedented 12th consecutive year, physicians and customers in 2007 ranked Pfizer’s US sales force Number One overall in the industry, according to an annual Verispan survey.
PUBLIC POLICY

2006/2007 KEY ACTIONS

Requested our US trade associations to disclose any portion of our dues used for political purposes.

Joined the Health Coverage Coalition for the Uninsured, to develop recommendations to address the uninsured in the American healthcare system.

Expanded the Pfizer Europe Advisory Council, which includes a range of stakeholders who advise Pfizer on healthcare issues.

Supported proposed legislation with the Campaign for Smokefree Air to help make Michigan the 30th US state to protect citizens from exposure to secondhand smoke. Please see www.pfizer.com/crreport.

Contributing to the Political Debate

Public policies have enormous impact on our ability to meet patient needs and create shareholder value. We have policies and procedures in place to ensure our activities are appropriate, ethical and transparent.

United States: Political Contributions

In the US we participate in one of the most heavily regulated industries and comply with all federal and state lobbying registration and disclosure laws. We disclose our political contributions twice a year, and have agreed to disclose any portion of our trade association dues that are used for political purposes. We publicly disclose on our website our corporate political contributions and employee Political Action Committee (PAC) contributions. To access Pfizer’s PAC Report, visit www.pfizer.com/responsibility/lobbying_and_political_contributions.jsp.

Supporting Drug Safety

FDA Revitalization Act (FDARA): The FDARA bill is the expansion of the reauthorization of the Prescription Drug User Fee Act (PDUFA), a law which requires the industry to pay fees to the agency for which the FDA is held to predictable regulatory review times and processes. The bill also includes provisions for drug safety legislation and pediatrics, specifically the Best Pharmaceuticals for Children Act and the Pediatric Research Improvement Act. This is the most comprehensive reform of the FDA in the past decade and Pfizer is actively supportive of this important legislation.

Working to Expand Health Insurance Coverage

For the past two years, Pfizer has participated in a diverse coalition of 16 groups including healthcare providers, trade associations and activist groups determined to rethink the issue and layout a path for progress. Together the groups developed consensus recommendations for covering a significant number of the uninsured and formed the Health Coverage Coalition for the Uninsured to move these recommendations forward. On January 18, 2007, the Coalition released an agreement which all parties endorsed. We are also working with the Coalition to Advance Health Reform.

Europe: Getting Stakeholder Input from Advisory Council

Pfizer Europe expanded the Europe Advisory Council to meet regularly with Pfizer management on commercial goals. To better serve patients, we included diverse social and economic interests, in addition to the medical and scientific interests, associated with particular medicines. For example, for Champix®, our smoking cessation medicine, we included diverse experts from international organizations, ministries of health, patients, trade unions and others, in addition to medical and scientific experts. Our understanding of how Champix® could better serve patients was enhanced, shifting us to a more “stakeholder focused” approach.

Egypt: Advancing Healthcare Reform

We’ve been working closely with the newly appointed Health Minister of Egypt to support his transparency and regulatory reform efforts. As a result, he issued a Ministerial Decree in 2006 designed to facilitate fast registration of innovative medicines and bring new products to market more quickly to help patients. Healthcare reform has become a top government priority.

China: Breaking Down HIV/AIDS Stigma

We worked closely with the Shanghai government to understand its health priorities. Among them was HIV/AIDS. Pfizer became the first multinational pharmaceutical company in China to issue an HIV/AIDS in the Workplace Policy that promotes a work environment free from harassment and discrimination for employees living with HIV/AIDS. This is part of a larger Pfizer public awareness program in Shanghai.

For more public policies around the world, please see our full corporate responsibility report at www.pfizer.com/crreport.

“The close partnership between Pfizer and our city has truly blossomed in the past decade. Over this period, our partnership has contributed to Shanghai’s development and to the health of our citizens. Looking ahead, we see our association growing stronger and deeper.”

—HAN ZHENG

MAYOR OF SHANGHAI
MANUFACTURING / SUPPLY CHAIN

2006/2007 KEY ACTIONS

Conducted more than 100 EHS onsite reviews at the facilities of contract manufacturers, researchers, key suppliers and outsourced logistic centers.

Continued to build a supplier base that reflects the changing demographics of the consumer marketplace.

Expanding Pfizer’s Responsible Contracting initiative across all Pfizer divisions in the US.

Improving EHS Performance of Contract Manufacturers and Key Suppliers

We use stringent environmental performance criteria to assess and select contract manufacturers and key Active Pharmaceutical Ingredient suppliers. We are also committed to helping our contract manufacturers and key suppliers in the developing world improve their Environment, Health and Safety (EHS) competency. To assure EHS responsibility in our supply chain, we conducted more than 100 onsite reviews at the facilities of contract manufacturers and researchers, key suppliers and outsourced logistic centers in 2006.

Increasing Supplier Diversity

Our Supplier Diversity initiative is designed to build a supplier base that reflects the changing demographics of the consumer marketplace while helping Pfizer increase shareholder value. To do this, we are:

- Increasing our spending with minority and women-owned businesses. Over several years, we have increased such spending by 10 percent a year.
- Partnering with advocacy organizations like WBENC and the National Minority Supplier Development Council to provide business development opportunities.

Responsible Contracting

Two years ago, we implemented a Responsible Contracting initiative in the US for use on all major capital projects, site services and services contracts. Pfizer was the first pharmaceutical company to do so. Under the initiative, contractors and service providers may bid to Pfizer provided they are paying appropriate wages, providing family health insurance and job training, complying with employment laws, and not using independent contractors. Over the past decade, more than $1.2 billion, or approximately 85 percent, of our construction dollars have gone to union contractors.

AWARDS AND RECOGNITION

- Working Mother named Pfizer one of the 100 Best Companies of 2006—the eighth time Pfizer was so honored.
- Pfizer earned a perfect score on the Human Rights Campaign Corporate Equity Index for the third year in a row.

EMPLOYEES

2006/2007 KEY ACTIONS

Developed a strategic plan endorsed by the Board of Directors to expand Pfizer’s global diversity and inclusion.

Initiated a global CEO-Colleague Advisory Committee to improve the flow of ideas.

Expanded Pfizer’s employee health improvement program.

Making Pfizer a Great Place to Work

Pfizer currently employs 89,000 people in more than 100 countries. One of the priorities of the senior management team is to make Pfizer a great place to work. This includes developing talent and employee engagement, which builds on meaningful work, an inclusive environment and effective leadership.

Striving for Enterprise-Wide Diversity

Diversity and inclusion is a key pillar of colleague engagement and productivity. In addition to attracting diverse employees, we are focusing on their development and engagement, so talented colleagues can make their way to senior levels. In 2006, Pfizer’s Board of Directors endorsed a comprehensive strategic plan to expand the company’s culture of diversity and inclusion globally. The plan revolves around platforms in: Leader Education and Accountability; Human Resources Processes; and Business Maximization and Growth. The program began rolling out in 2007.

Communicating Openly

We launched a variety of new ways to engage colleagues in interactive communication to open dialogue between employees and senior management.
Looking Ahead

We are looking for sustainable ways to meet healthcare needs around the world, today and tomorrow. We strive to help people get needed treatments and services, while fostering a climate of innovation that ensures steady progress in biomedical science.

Certainly, our work in research and development, prevention and wellness, and healthcare reform helps empower people in their own healthcare. But given the complexities of global healthcare issues, we cannot solve problems alone.

So, we will listen, learn and change, and work hard with responsible business practices, in partnership with our stakeholders, to help create a healthier, wealthier world.

That is our commitment.
To download the complete Corporate Responsibility Report, please visit www pfizer com/crreport.

About the Summary Report

We are pleased to issue a summary of Pfizer’s second report on our corporate responsibility approach and activities. More detailed information is available on our website at www pfizer com/crreport. There is also a brochure version in print and on the web at www pfizer com/crreport.

Scope of Reporting

This summary report covers Pfizer’s pharmaceutical and animal health businesses. Pfizer’s consumer products business was sold to Johnson & Johnson at the end of 2006. This summary report includes activities and data from the calendar year 2006, from our consumer products business. The environmental performance data does not include our consumer products business. Additional updates from 2007 are referenced where relevant.

Materiality

The content of this summary report is based on a materiality analysis focusing on two key factors—the importance to stakeholders and the potential to influence business strategy. Materiality was assessed by an internal cross-divisional team representing the key businesses and by an external advisory group.

Stakeholder Inclusiveness

We listen to our stakeholders and value their perspectives. In keeping with the principle of stakeholder inclusiveness, we have identified our stakeholders in this report, the feedback we have received, and how we have responded to their expectations and interests.

Progress on 2006 Commitments

For progress on our 2006 commitments made in our previous Corporate Responsibility (CR) Report, please see the complete 2007 CR Report on www pfizer com/crreport. Given the transition that Pfizer is undergoing, commitments for 2008 will be posted on the CR website in 2008.

Global Reporting Initiative

Sustainability Reporting Guidelines

The complete corporate responsibility report on the web includes a Global Reporting Initiative (GRI) index based on its Sustainability Reporting Guidelines (G3). We self-declare that report to be GRI Application Level B.

To Contact Us

Please see www pfizer com/contact.

This Summary Report is printed on process chlorine-free FSC-certified Mohawk Options 100% PC, which is made with 100% post-consumer recycled fiber. The emissions from the electricity used to manufacture this paper are offset with credits from Green-e certified windpower projects. This paper is also certified by Green Seal.

Design: Ideas On Purpose, New York